Daiichi Sankyo Contributes to Relief Efforts for Countermeasures against COVID-19

Tokyo, Japan (April 14, 2020) – Daiichi Sankyo Company, Limited (hereinafter, “Daiichi Sankyo”) today announced that, through the Japan Center for International Exchange*1, it will make a donation of $1 million to the COVID-19 Solidarity Response Fund*2 in support of relief efforts for countermeasures against COVID-19.

Daiichi Sankyo decided to provide this donation as part of our global contribution to society in light of the need for global support of measures against COVID-19 and concerns about the rapid spread of infection in the future in areas where access to healthcare is inadequate.

In addition, Daiichi Sankyo group companies in the world have already provided a variety of support, including donations, to meet specific needs in each country and region. The details of such support will be made public as they become available through the page entitled, “Our Company’s Efforts to Limit the Spread of the Virus that Causes COVID-19,” on our corporate website.

Daiichi Sankyo would like to express our sincere sympathy to all the people around the world who have been adversely affected by the novel coronavirus; moreover, Daiichi Sankyo sincerely wishes for the speedy recovery of those persons afflicted, and we hope for an end to the pandemic as soon as possible.
The Japan Center for International Exchange is a public benefit foundation that conducts various projects to strengthen the international role of the Japanese public and private sector in the field of international health.

The COVID-19 Solidarity Response Fund for WHO is a fund established to support the work of the World Health Organization (WHO) and powered by the United Nations Foundation and the Swiss Philanthropy Foundation to support rapid responses to COVID-19, such as the prevention and detection of pandemics.

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com/